ANDA 79187, held by Pharmobedient. Pravastatin Sodium.
As of Nov 16, 2026, ANDA 79187 (Pravastatin Sodium), held by Pharmobedient, was first approved by FDA on May 27, 2010, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 27, 2010 | Original application | Approved | None posted |
| Pravastatin Sodium10MG · tablet;oral | Pravastatin Sodium | Discontinued |
| Pravastatin Sodium20MG · tablet;oral | Pravastatin Sodium | Discontinued |
| Pravastatin Sodium40MG · tablet;oral | Pravastatin Sodium | Discontinued |
| Pravastatin Sodium80MG · tablet;oral | Pravastatin Sodium | Discontinued |
| Mar 17, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| May 30, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| May 30, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jun 4, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 1, 2015 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 17, 2012 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 27, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters